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1. Introduction
Traumatic brain injury (TBI) is a major source of death and severe disability worldwide. In
the USA alone, this type of injury causes 290, 000 hospital admissions, 51, 000 deaths, and
80, 000 permanently disabled survivors [1, 2]. TBI occurs in two phases, primary and secon‐
dary brain injury. The primary injury results from the direct physical impact to the brain pa‐
renchyma resulting in structural and shearing injury of neurons, injury to vessels, and
interruption of neurochemical processes. This leads to hemorrhage, edema, compression of
intracranial structures. Primary injury is unalterable after the time of the trauma.The secon‐
dary injury, on the other hand, is characterized by a cascade of events that starts within mi‐
nutes of the primary injury. As in ischemia –reperfusion injuries, the acute post-injury
period in TBI is characterized by several pathophysiologic processes that start in the mi‐
nutes to hours following injury and may last for hours to days. These result in further neu‐
ronal injury and are termed the secondary injury. The causes of the secondary injury can be
evaluated by those that occur of the systemic or extracerebral level and those that occur on
the cellular level. On the systemic level contributing factors include hypoxia, hypotension,
hypercapnia, acidosis and hyperglycemia [3, 4].While the cellular mechanisms of secondary
injury include all of the following: apoptosis, mitochondrial dysfunction, excitotoxicity, dis‐
ruption in ATP metabolism, disruption in calcium homeostasis, increase in inflammatory
mediators and cells, free radical formation, DNA damage, blood-brain barrier disruption,
brain glucose utilization disruption, microcirculatory dysfunction and microvascular throm‐
bosis [5-8]. All this leads to development of cerebral edema, blood-brain barrier disruption,
vasospasm, increase in volume of bleeding and contusions, and intracranial hyperten‐
sion.TBI patients, like other patients with brain injury, need multidisciplinary approach
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(neurointensivists, neurologists, neurosurgeons, and specialized nurses, respiratory thera‐
pists, physical therapists, nutritionists, etc.) for improved outcomes. Mortality and function‐
al outcomes in all brain injured patients, including TBI patients improve when monitored
and managed in neuroICUs and by neurointensivists [9-12]. This chapter will focus on the
management of TBI patients in the intensive care unit.
2. Neurological assessment
The most widely used and most studied coma scale to date is the Glasgow coma scale (GCS)
(Figure 1), first described by Teasdale and Jennett in 1974 and revised in 1976 with the addi‐
tion of a sixth point in the motor response subscale for ‘‘withdrawal from painful stimulus’’
[13, 14]. The GCS was initially intended to assess level of consciousness after TBI in a Neuro‐
surgical Intensive Care Unit (Neuro-ICU) [13].The GCS was broadly accepted as an instru‐
ment to classify the severity of TBI because it was easy to use and reproducible. It was used
to classify the severity of TBI as mild (GCS 13-15), moderate (GCS 9-12), and severe (GCS 8
and below) [15, 16]. Since then it has become the gold standard against which newer scales
are compared. As a result, the GCS was incorporated into several scoring systems, including
the APACHE II [17], the Simplified Acute Physiology Score (SAPS) and SAPSII [18], the Re‐
vised Trauma Score (RTS) [19], the Circulation, Respiration, Abdomen, Motor, Speech scale
(CRAMS) [20], the Traumatic Injury Scoring System (TRISS) [21], and A Severity Characteri‐
zation of Trauma (ASCOT) scale [22], all of which are used to score the severity and predict
outcome of TBI. However, the reliability of GCS in predicting patient outcomes is unsatis‐
factory, especially with regard to the verbal component. As a result, Widjicks et al. publish‐
ed a new scoring system in 2005, the Full Outline of UnResponsiveness (FOUR) score
(Figure 2), a newer scale, developed to provide a more comprehensive assessment [23]. The
FOUR score includes additional information not assessed by the GCS like brainstem reflex‐
es, visual tracking, breathing patterns, and respiratory drive [23] (Figure 2). It is also more
practical for evaluating critically ill intubated patients, as it does not depend on an evalua‐
tion of the verbal response. It has already been validated in various populations of comatose
patients, including TBI patients [24-30]. While GCS lacks the ability to identify subtle
changes in alteration of consciousness, the FOUR score assesses four variables: eye response,
motor response, brainstem reflexes, and respiration pattern (Figure 2). The acronym also re‐
flects the number of categories and the maximum number of potential points in each catego‐
ry, making it fairly simple to use and remember. In addition, the FOUR score can account
for the intubated patient and can also differentiate between a locked-in state and a vegeta‐
tive state, via the addition of testing eye tracking, thus incorporating midbrain and pontine
functions, effectively allowing the examiner to localize lesions. Another advantage for the
FOUR score is that is gives all components equal weight, making it linear which is ideal for
a coma scale compared to the GCS score is weighted toward motor responses. The GCS
scale does offer the benefit of rapid evaluation in the emergency department, it is readily re‐
producible by multiple personal, from nursing staff to trauma surgeons, and gives a rapid
assessment of the severity of injury. This is likely attributable to its long standing applica‐
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tion in the field, which makes it second nature for many to communicate the information.
More studies are needed to favor one over the other. For now, using either GCS or FOUR
score for initial neurological assessment as well as follow up neurologic checks is acceptable.
Figure 1. Glasgow Coma Scale
3. Intracranial pressure monitoring
Intracranial hypertension develops commonly in acute brain injury related to trauma [31,
32]. Raised Intracranial pressure (ICP) is an important predictor of mortality in patients with
severe TBI, and aggressive treatment of elevated ICP has been shown to reduce mortality
and improve outcome (32-39). Guidelines for the Management of Severe TBI, published in
the Journal of Neurotrauma in 2007 [4] make a Level II recommendation that ICP should be
monitored in all salvageable patients with a severe TBI (Glasgow Coma Scale [GCS] score of
3–8 after resuscitation) and an abnormal computed tomography (CT) scan. ICP monitoring
is also recommended in patients with severe TBI and a normal CT scan if two or more of the
following features are noted at admission: age over 40 years, unilateral or bilateral motor
posturing, or systolic blood pressure < 90 mm Hg (Level III recommendation). In comatose
TBI patients with an abnormal CT scan, the incidence of ICH was 53–63% [40]. Patients with
a normal CT scan at admission, on the other hand, had a relatively low incidence of intracra‐
nial hypertension (13%). However, within the normal CT group, if patients demonstrated at
least two of three adverse features (age over 40 years, unilateral or bilateral motor posturing,
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Figure 2. Full Outline of UnResponsiveness (FOUR) score. Eye response: E4 eyelids open or opened, tracking, or blink‐
ing to command; E3 eyelids open but not tracking; E2 eyelids closed but open to loud voice; E1 eyelids closed but
open to pain; and E0 eyelids remain closed with pain. Motor response: M4 thumbs-up, fist, or peace sign; M3 localiz‐
ing to pain; M2 flexion response to pain; M1 extension response to pain; and M0 no response to pain or generalized
myoclonus status. Brainstem reflexes: B4 pupil and corneal reflexes present; B3 one pupil wide and fixed; B2 pupil or
corneal reflexes absent; B1 pupil and corneal reflexes absent; and B0 absent pupil, corneal, and cough reflex. Respira‐
tion pattern: R4 not intubated, regular breathing pattern; R3 not intubated, Cheyne-Stokes breathing pattern; R2 not
intubated, irregular breathing; R1 breathes above ventilatory rate; and R0 breathes at ventilator rate or apnea.
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or systolic BP < 90 mm Hg), their risk of intracranial hypertension was similar to that of pa‐
tients with abnormal CT scans [4]. ICP is a strong predictor of outcome from severe TBI [33,
34, 36, 41-43]. Because of this, ethically a randomized trial of ICP monitoring with and with‐
out treatment is unlikely to be carried out. Similarly, a trial for treating or not treating sys‐
temic hypotension is not likely. Both hypotension and raised ICP are the leading causes of
death in severe TBI. Furthermore, several studies have shown that patients who do not have
intracranial hypertension or who respond to ICP-lowering therapies have a lower mortality
than those who do not respond to therapy [5-12, 44-47]. As a result, Guidelines for the Man‐
agement of Severe TBI recommend that treatment should be initiated with ICP thresholds
above 20 mm Hg (level II) as well as target a cerebral perfusion pressure (CPP) within the
range of 50-70 (level III) [4]. Prevention and/or treatment of intracranial hypertension is
commonly accomplished by employing a progression of therapeutic approaches that are ef‐
ficacious in controlling ICP and uniformly believed to be easily applied with minimal or
rare negative side effects. These measures include(but are not limited to): elevation of the
head of the bed, avoiding hypotension, hypoxia, and hypercapnea or prolonged hypocap‐
nea, intravenous sedation and analgesia, administration of hyperosmolar agents (mannitol,
hypertonic saline), and CSF drainage [4].
4. Oxygenation and ventilation
Hypoxia (PaO2 < 60 mmHg or O2 saturation < 90%) worsens secondary brain injury and
thus significantly worsens outcome in patients with TBI [48, 49]. In addition, duration of hy‐
poxemia (median duration ranging from 11.5 to 20 min) was found to be an independent
predictor of mortality [50]. Elevated Carbon dioxide dilates the cerebral blood vessels, in‐
creasing the volume of blood in the intracranial vault and therefore increasing ICP [51]. On
the other hand, hyperventilation leads to cerebral vasoconstriction, and thus can result in
cerebral ischemia, despite possible improvements in CPP and ICP [52]. Thus, hyperventila‐
Figure 3. Oxygen tension and carbon dioxide effects on Cerebral Blood flow
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tion is recommended only as a temporizing measure to reduce an elevated ICP, preferably
not below 30 mmHG unless absolutely necessary and only for few minutes while determin‐
ing an etiology of the intracranial hypertension and initiating other treatment options or sur‐
gical intervention. The ventilator settings should be adjusted to maintain normoxia with a
pulse oximetry (SpO2) around 95% or PaO2 around 80 mm Hg and eucapnia with PaCO2 of
35 to 40 mm Hg (in patients with chronic CO2 retention, such as COPD patients, CO2
should be maintained close to their baseline CO2 and normal pH). (Figure 3) At this point it
is worth mentioning acute lung injury (ALI) and acute respiratory distress syndrome
(ARDS). The incidence of ALI/ARDS in TBI is reported between 10 % and 30 % [53, 54]. ALI/
ARDS could develop secondary to aspiration, pneumonia, pulmonary contusion, massive
blood transfusion, transfusion-related ALI (TRALI), sepsis, or neurogenic pulmonary ede‐
ma. Management of ALI/ARDS entails low tidal volumes, higher positive end expiratory
pressure, and permissive hypercapnea [55]. However, as mentioned above, hypercapnea (>
40 mmHG) is contraindicated in TBI patients with intracranial hypertension. One needs to
balance need for low tidal volume and CO2 levels, and thus frequent ABG measurements is
warranted.
5. Blood pressure and cerebral perfusion
Hypotension (SBP < 90 mm Hg) can worsen secondary injury in TBI and is associated with
worsening mortality and neurologic outcomes [56, 57]. In TBI patients from the Trauma Co‐
ma Data Bank, early hypotension occurred in 34.6% of patients with severe traumatic brain
injury and was shown to double the mortality rate (55% versus 27%). Late hypotension (in
the ICU) occurred in 32% of patients. For patients whose only hypotensive episode occurred
in the ICU, 66% died or were vegetative survivors compared with 17% of patients who nev‐
er had a hypotensive episode [56]. We recommend IVF resuscitation to maintain euvolemia,
using either invasive (e.g. CVP or pulmonary capillary wedge pressure) or noninvasive
methods (e.g. Echocardiogram or NICOM-noninvasive cardiac output monitoring) to meas‐
ure either static (CVP) or dynamic (Stroke volume index variation) surrogates of intravascu‐
lar volume and hemodynamics. Hypotonic, hyponatremic, and sugar containing fluids
should be avoided. If patient is euvolemic and remains hypotensive, then vasopressors
should be started to maintain adequate blood pressure. Cerebral perfusion pressure is de‐
fined as mean arterial pressure (MAP) minus ICP (CPP = MAP – ICP). CPP < 60 mm HG
should be avoided since it is associated with poor outcomes in patients with TBI [58]. Both
60 mmHg and 70 mm Hg are cited in the literature as the threshold above which CPP
should be maintained. However, as reported earlier, the Guidelines for the Management of
Severe Traumatic Brain injury recommend maintaining CPP between 50-70 mmHg [4]. In
our patients, when the neurologic status is stable with a normal ICP, aggressive measures
do not need to be taken as long as CPP >50 mmHg. Conversely, in patient’s where exam is
poor or ICP has been elevated/required treatment, then would recommend CPP >60 mmHg
since the risk of secondary injury developing is more imminent in these patients. In the ab‐
Traumatic Brain Injury150
sence of cerebral ischemia, aggressive attempts to maintain CPP above 70 mmHg with fluids
and vasopressors should be avoided because of the risk of ARDS [59].
6. Hyperosmolar therapy
Brain parenchyma is 80% water, and thus brain volume is very responsive to changes in wa‐
ter content. A hyperosmolar agent creates a gradient for water to move from brain paren‐
chyma to the intravascular space across the blood-brain barrier (BBB). As a result, the
effectiveness of a hyperosmolar agent depends on the extent it is prevented from crossing
the BBB. Both mannitol and hypertonic saline posses this property and will be discussed in
this section. Mannitol is given in a 20% or 25 % solution in boluses of 0.25 to 1.0 g per kilo‐
gram of body weight at intervals of 2, 4, 6, or more hours. In addition to the osmotic proper‐
ties of mannitol, , it also lowers blood viscosity which leads to increase cerebral blood flow
resulting in cerebral vasoconstriction (autoregulation), which in turn reduces cerebral blood
volume and thus intracranial pressure [60]. In patients with impaired cerebral autoregula‐
tion, aggressive use of mannitol could result in increased ICP. As this implies, for mannitol
to be fully effective, the blood brain barrier must be intact. In patients where the BBB is not
intact, mannitol crosses the BBB and can draw fluid into brain resulting in an increase in ICP
[61, 62], hence concentrations of mannitol should be assessed before each dose. Instead of
measuring actual mannitol, an easier and more practical way is to measure serum osmolari‐
ty or osmolar gap (measured – calculated serum osmolarity) before infusing mannitol. Be‐
cause of the above as well as to minimize risk of acute kidney injury, Mannitol should thus
not be given if serum osmolarity is more than 320 mOsm/Kg H2O or osmolar gap > 10. Side
effects of mannitol include hypotension, hypovolemia, hypokalemia, hyperkalemia, and
acute kidney injury [63, 64]. Mannitol is contraindicated in patients with renal failure. Hy‐
pertonic saline increases serum osmolarity directly rather than by inducing osmotic dieresis,
as well as by viscosity-related cerebral vasoconstriction [65]. It is used in a 3% solution infu‐
sion or in boluses of approximately 150 ml, in a 7.5% solution in 75-ml boluses, or in a 23.4%
solution in 30-ml boluses every 2, 4, 6, or more hours. Serum osmolarity and serum sodium
should be checked before dosing hypertonic saline. Hypertonic saline should not be given if
serum Na is more than 160 mmol/liter. Side effects of hypertonic saline include fluid over‐
load secondary to intravascular volume expansion, acidosis, hypokalemia, and hyperchlore‐
mia. There is a potential for development of central pontine myelinolysis with rapid increase
in serum Na concentration, however, this phenomenon has not been documented in this sce‐
nario of management of intracranial hypertension. The question remains as to which one,
mannitol or hypertonic saline, is superior? Recent evidence including two metanalysis, sug‐
gest that hypertonic saline may be more effective than mannitol in reducing ICP [66-69],
however, high quality studies comparing the agents, while accounting for side effects and
contraindications are lacking. Furthermore, it is very important to take into consideration
patient characteristics, such as volume status, renal function, hemodynamic status, sodium
levels, etc.., when choosing the appropriate hyperosmolar agent. Hyperosmolar therapy
should be weaned gradually rather than stopped abruptly in the days to follow.
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7. Refractory intracranial hypertension: Therapeutic hypothermia and
barbiturate coma
Refractory intracranial hypertension (RICH) is defined as intracranial pressures that exceed
25 mm Hg for 30 minutes, 30 mm Hg for 15 minutes, or 40 mm Hg for 1 minute despite tier
1 and tier 2 therapies [70]. Tier 1 therapies include head of patient’s bed at or more than 30
degrees, adequate sedation and analgesia, and adequate CSF draining if ICP is monitored by
ventriculostomy. Tier 2 therapies include adequate hyperosmolar therapy ( mannitol or hy‐
pertonic saline or both), mild hyperventilation (pCO2 goal of 30 – 35 mmHg), and neuro‐
mascular blockade. RICH occurs in approximately 15% of patients with traumatic brain
injury [70]. If it is not aggressively treated, RICH can result in cerebral herniation and
death.High-dose barbiturate administration is recommended to control elevated ICP refrac‐
tory to maximum standard medical and surgical treatment (level II) [3]. High-dose barbitu‐
rates have been scarcely studied for this indication. In 2004, the Cochrane Injuries Group
performed a systematic review of the barbiturate RCTs. In the only two studies examining
the effect on ICP, the relative risk for refractory ICP with barbiturate therapy was 0.81 (95%
CI 0.62–1.06). Concerning this indication, the Cochrane group concluded: “There is no evi‐
dence that barbiturate therapy in patients with acute severe head injury improves outcome.
Barbiturate therapy results in a fall in blood pressure in one of four treated patients. The hy‐
potensive effect of barbiturate therapy will offset any ICP lowering effect on cerebral perfu‐
sion pressure” [71]. Significant side effects of barbiturates include hypotension, arrhythmias,
immunosuppression, hepatotoxicity, fever and injection site reactions. The Guidelines for
the Management of Severe TBI recommend that more studies are needed to identify alterna‐
tive agents for this indication - “elevated ICP refractory to standard therapy” [3]. Albeit
small, there are more RCT evaluating the effect of therapeutic hypothermia on ICH in severe
TBI (13 studies) than for barbiturates; all consistently demonstrating that hypothermia is ef‐
fective in controlling ICP (This is reviewed in more detail elsewhere : Farid Sadaka, Christo‐
pher Veremakis, Rekha Lakshmanan and Ashok Palagiri (2013). Therapeutic Hypothermia
in Traumatic Brain Injury, Therapeutic Hypothermia in Brain Injury, Dr. Farid Sadaka (Ed.),
ISBN: 978-953-51-0960-0, InTech, DOI: 10.5772/48818. Available from: http://www.intechop‐
en.com/books/therapeutic-hypothermia-in-brain-injury/therapeutic-hypothermia-in-trau‐
matic-brain-injury). Complications from hypothermia include electrolyte imbalances,
increase in incidence of infections, thrombocytopenia, coagulopathy, arrhythmias (especially
bradycardia), pancreatitis, and rebound ICH (during re-warming). In one extensive review
[72], Povlishock et al showed that posttraumatic hypothermia followed by slow rewarming
appeared to provide maximal protection in terms of traumatically induced axonal damage,
microvascular damage and dysfunction, contusional expansion, intracranial hypertension,
and neurocognitive recovery. In contrast, hypothermia followed by rapid rewarming not
only reversed the protective effects associated with hypothermic intervention, but exacerbat‐
ed the traumatically induced pathology and its neurologic consequences. Povlishock’s re‐
view concluded that the rate of posthypothermic rewarming is an important variable in
assuring maximal efficacy following the use of hypothermic intervention. The most chal‐
lenging issue appears to be rebound ICP during re-warming. We suggest that re-warming
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only be considered if the patient’s ICP is stable and <20mmHg for at least 48 hours, and,
thereafter implemented at a rate not faster than 0.1 -0.25°C per hour. Surgical management
of TBI patients such as Decompressive hemi-craniectomy or bilateral craniectomy are dis‐
cussed in more detail in chapter http://www.intechopen.com/books/traumatic-brain-injury/
surgical-treatment-of-severe-traumatic-brain-injury. Please refer to figure 4 for protocolized
step-wise approach to ICP management.
Figure 4. Stepwise approach to management of intracranial hypertension.
8. Temperature modulation and normothermia
Aside from role of hypothermia in ICP control in patients with refractory intracranial hyper‐
tension, therapeutic hypothermia has also been studied as a primary neuroprotectant in pa‐
tients with severe TBI, based on the fact that early administration of TH could halt the
secondary injury processes discussed above, and thus possibly improve outcome. This topic
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is reviewed in more detail elsewhere : Farid Sadaka, Christopher Veremakis, Rekha Laksh‐
manan and Ashok Palagiri (2013). Therapeutic Hypothermia in Traumatic Brain Injury,
Therapeutic Hypothermia in Brain Injury, Dr. Farid Sadaka (Ed.), ISBN: 978-953-51-0960-0,
InTech, DOI: 10.5772/48818. Available from: http://www.intechopen.com/books/therapeutic-
hypothermia-in-brain-injury/therapeutic-hypothermia-in-traumatic-brain-injury. In short,
although single-center studies were encouraging, multicenter trials with early administra‐
tion of hypothermia for a defined period of time irrespective of ICP have almost uniformly
been negative except maybe for patients undergoing craniotomy for hematoma evacuations.
However, hypothermia was maintained for a fixed duration of only 48 hrs, and ICP eleva‐
tions mainly occurred during and after rewarming. These results suggest that a period of 48
hours of hypothermia may be too short to have a beneficial effect on outcome. A standar‐
dized one size fit all may be inappropriate. The rate of rewarming plays an important role as
well as pointed above.The rebound increase in ICP during and after rewarming in these
studies and the encouraging outcomes from the randomized studies that induced hypother‐
mia early and continued it throughout the period of intracranial hypertension point to the
realization that individualizing the duration of hypothermia to fit a patient’s ICP in future
trials may be a better strategy than a predetermined period of hypothermia regardless of
ICP. As for now, therapeutic hypothermia cannot be recommended for TBI patients aside
from control of refractory ICP discussed above.All of the mechanisms of secondary brain in‐
jury in TBI discussed above (apoptosis, mitochondrial dysfunction, excitotoxicity, disruption
in ATP metabolism, disruption in calcium homeostasis, increase in inflammatory mediators
and cells, free radical formation, DNA damage, blood-brain barrier disruption, brain glu‐
cose utilization disruption, microcirculatory dysfunction and microvascular thrombosis ) are
temperature dependant. They are all stimulated and exacerbated by fever [73]. In addition,
fever occurs with high frequency in this patient population, with up to 68% of patients expe‐
riencing at least one fever during their intensive care unit stay [74]. Fever in the TBI popula‐
tion may result from multiple causes and for reasons other than infection and has proven
difficult to control. Disruption of the hypothalamic set point, tissue ischemia/infarction, sur‐
gery, medications, and blood product transfusions may all induce hyperthermia. Early hy‐
perthermia following TBI is associated with a longer ICU length of stay and worsened
neurologic outcomes [75-77]. Thereby, temperature should be controlled, fever should be ag‐
gressively treated, and normothermia should be maintained in patients with TBI.
9. Nutrition and glucose control
TBI, especially severe TBI, can cause increase metabolism and can create a hypercatabolic
state that results in rapid depletion of nutrition reserves, as well as worsening immune func‐
tion and morbidity [78, 79]. In TBI patients, adequate nutrition that is started early after in‐
jury is associated with enhanced immunity, decreased infectious morbidity, shortened
length of hospitalization, improved neurological recovery and reduced mortality [80, 81].
Brain trauma foundation recommends that patients should be fed to attain full caloric re‐
placement by day 7 post-injury [3]. American Society for Parenteral and Enteral Nutrition
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(ASPEN) for nutrition support in critically-ill adult patients suggest that enteral nutrition
should be started within the first 24–48 h following admission, as long as patients are hemo‐
dynamically stable [82]. The European Society for Parenteral and Enteral Nutrition (ESPEN)
recommends initiating enteral nutrition within 24 h if possible [83]. Despite popular belief,
recent evidence reiterates that bowel sounds and passing flatus or stool are not required for
the initiation of enteral nutrition[82]. In circumstances when early enteral nutrition cannot
be initiated, parenteral nutrition should be strongly considered.There is no question that hy‐
perglycemia is associated with worse outcome in brain injured patients [84, 85]. Hypoglyce‐
mia leads to deprivation of the brain of its fuel which can lead to compromised brain energy
metabolism and worsen the already existent brain injury, especially during the increase in
glucose utilization and brain energy demand observed after TBI [86, 87]. However, the opti‐
mal target for systemic glucose control is not known. In patients with severe brain injury,
tight systemic glucose control (80–120 mg/dL) was associated with reduced cerebral extrac‐
ellular glucose availability and increased prevalence of brain energy crisis, which in turn
correlates with increased mortality [88]. Intensive insulin therapy may thus impair cerebral
glucose metabolism after severe brain injury. Based on the existing low quality evidence, the
most recent guidelines from the Society of Critical Care Medicine (SCCM) suggest that
blood glucose (BG) ≥ 150 mg/dL should trigger initiation of insulin therapy for most patients
admitted to an ICU with the diagnosis of TBI, titrated to achieve BG values absolutely < 180
mg/dL, to minimize the adverse effects of hyperglycemia [89]. The guidelines also suggest
that BG < 100 mg/dL be avoided during insulin infusion for patients with brain injury [89].
10. Anemia and transfusion
Hypoxia and hypotension worsen secondary brain injury and are important determinants of
outcome in TBI patients. They both are associated with worse outcomes as discussed above.
This could be the reason why many patients with TBI are still transfused to a hemoglobin
threshold of 10 g/dl. Although red blood cells are an essential requirement for the transport
of oxygen to the tissues, several problems are documented with red blood cells (RBC) trans‐
fusions such as infection, pulmonary complications such as transfusion-related acute lung
injury (TRALI) and transfusion-associated circulatory overload (TACO), transfusion-related
immunomodulation (TRIM) and multiorgan failure, and increased mortality [90]. Besides,
there is no clear correlation between anemia and hypoxia or hypotension in TBI patients. In
one retrospective study, linear regression showed that more days with hematocrit < 30%
was associated with improved neurologic outcomes. In addition, transfusion of RBCs was
significantly associated with worse outcomes [91]. In a subgroup analysis of a multicenter
randomized controlled clinical trial involving 67 critically ill patients from the Transfusion
Requirements in the Critical Care trial who sustained a closed head injury, patients were
randomized to a restrictive RBC transfusion strategy (Hb 7.0 g/dL and maintained between
7.0 and 9.0 g/dL) or a liberal strategy (Hb 10.0 g/dL and maintained between 10.0 and 12.0 g/
dL). This study was unable to detect significant improvements in mortality with a liberal as
compared with a restrictive transfusion strategy in critically ill trauma patients with moder‐
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ate-to severe TBI [92]. Guidelines for transfusion developed by EAST (Eastern Association
for Surgery of Trauma) and the American College of Critical Care Medicine (ACCM) of the
Society of Critical Care Medicine (SCCM) state that there is no benefit of a “liberal” transfu‐
sion strategy (transfusion when Hb is <10 g/dL) in patients with moderate-to-severe TBI
[93]. Large multicenter prospective studies are needed to evaluate the effects of anemia and
RBC transfusion in patients with TBI.
11. Deep venous thrombosis
The application of chemical venous thrombo-embolism (VTE) prophylaxis traumatic brain
injury patients has been long been guided by the dogma of physicians practicing under as‐
sumptions rather than evidenced based guidelines. This has resulted in the blanket denial of
the use of any chemical DVT prophylaxis up until more recent years, despite the common
knowledge that trauma patient are at high risk for development of venous thromboembolic
events. The overwhelming fear associated with propagating the intracranial injury has also
limited the number of studies until recently. Most of the data that is currently applied to
support the safety of chemical prophylaxis has been extrapolated from studies that were
performed looking that the risks of post-operative hemorrhage in elective craniotomy pa‐
tients. In 1998 Agnelli et. al. compared the use of enoxaparin combined with compression
stockings to patients treated with compression stockings alone and found a significant re‐
duction in the number of VTE without any increase in hemorrhage after elective neurosur‐
gery [94]. This study and others like it opened the door for further application and research
in the area of traumatic brain injury. The current formal recommendation by the Guidelines
for the Management of Severe Traumatic Brain Injury 2007 state that the use of low-molecu‐
lar weight heparin or low dose unfractionated heparin should be used in combination with
mechanical prophylaxis, but there is an increased risk for expansion of intracranial hemor‐
rhage. There is insufficient evidence to support recommendations regarding the preferred
agent, dose, or timing [4].The lack of guidelines to follow has prompted many institutions to
develop their own guidelines based on extrapolated data and to record and report their ex‐
periences. In 2010, clinicians at McGill University published their findings, which showed
an acceptable VTE control rate without increased risk of expanding intracranial hemorrhage
[95]. The general principles that predominate in the use of chemical VTE prophylaxis are the
following: 1) patients not expected to go to the operating room in the next 24 hours for intra‐
cranial procedure 2) no evidence of systemic coagulopathy 3) 2 stable CT scans. All guide‐
lines should be applied with the consideration of the injuries of the specific patient in
question and altered as seen appropriate for the situation. The first phase of a randomized,
double-blind study involving the early use of enoxaparin in trauma patients was just pub‐
lished in 2012 [96]. The study found at 2.3% higher rate of progression in the patients treated
with enoxaparin over placebo, however, none were clinically significant. DEEP-II is intend‐
ed to evaluate the efficacy of this VTE prevention and DEEP-III will apply to moderate-risk
patients. A recently published systematic review and meta-analysis of the use of early chem‐
ical VTE prophylaxis in TBI patients found that it reduced the risk of VTE without progres‐
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sion of intracranial hemorrhage [97]. While there is certainly the need for more studies to
quantify the risk associated with the early use of chemical VTE prophylaxis, there is evi‐
dence that supports the appropriate application in traumatic brain injury patients at high
risk for developing DVT. Although we cannot not provide official recommendations, dos‐
age, or timing of administration, it is used in our institution.
12. Conclusion
TBI is a devastating injury and often these patients would require monitoring and treatment
in intensive care unit. Management of TBI patients requires multidisciplinary approach, fre‐
quent close monitoring and judicious use of multiple treatments to lessen secondary brain
injury and improve outcomes. There is a lot of opportunity for further research in TBI, in‐
cluding but not limited to multimodal monitoring, and therapeutics to further improve out‐
comes in this very common mechanism of brain injury.
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